Philadelphia, PENNSYLVANIA3 Active Studies

Triple Negative Breast Cancer Clinical Trials in Philadelphia, PENNSYLVANIA

Find 3 actively recruiting triple negative breast cancer clinical trials in Philadelphia, PENNSYLVANIA. Connect with local research sites and explore new treatment options.

3
Active Trials
2
Sponsors
300
Enrolling

Recruiting Triple Negative Breast Cancer Studies in Philadelphia

About Triple Negative Breast Cancer Clinical Trials in Philadelphia

Triple-negative breast cancer (TNBC) lacks estrogen receptors, progesterone receptors, and excess HER2 protein, limiting targeted treatment options. It accounts for about 10-15% of breast cancers and tends to be more aggressive. Active research focuses on immunotherapy and novel drug combinations.

There are currently 3 triple negative breast cancer clinical trials recruiting participants in Philadelphia, PENNSYLVANIA. These studies are seeking a combined 300 participants. Research is being sponsored by Laura Huppert, MD, BA, Dana-Farber Cancer Institute. Clinical trial participation is free and participants receive study-related medical care at no cost.

Triple Negative Breast Cancer Clinical Trials in Philadelphia — FAQ

Are there triple negative breast cancer clinical trials in Philadelphia?

Yes, there are 3 triple negative breast cancer clinical trials currently recruiting in Philadelphia, PENNSYLVANIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Philadelphia?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Philadelphia research site will contact you about next steps.

Are clinical trials in Philadelphia free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Philadelphia studies also compensate for your time and travel.

What triple negative breast cancer treatments are being tested?

The 3 active trials in Philadelphia are testing new therapies including novel drugs, biologics, and treatment approaches for triple negative breast cancer.

Data updated March 2, 2026 from ClinicalTrials.gov